Skip to main content
. 2021 May 7;100(18):e25784. doi: 10.1097/MD.0000000000025784

Figure 2.

Figure 2

Measures of multiple myeloma burden and clinical responses to infusions of anti-BCMA chimeric antigen receptor T (CAR-T) cells of case 1. (A) A total of 72 hours after CAR-BCMA infusion, the patient became febrile. She was febrile for 4 days. The plot shows the maximum temperature for each day. The levels of IL-6 and CRP were elevated. (B) Panel B shows the trend in IgG and M spike concentrations after treatment with anti-BCMA CAR-T cell infusion. (C) Bone marrow cells were 0.94% plasma cells as shown by CD38 staining at 13 days before the anti-BCMA CAR-T cell infusion. BCMA expression per flow cytometry showed uniform BCMA expression on CD38-positive malignant plasma cells before the anti-BCMA CAR-T cell infusion. (D) No plasma cells were found among the bone marrow cells on day 30 after anti-BCMA CAR-T cell infusion. BCMA = B-cell maturation antigen, CRP = C-reactive protein, IL = interleukin, SSC-A = side scatter area.